Immunologic Factor
palivizumab
Brand Names:
Synagis
Effect:
Decreased Cell Wall Synthesis & Repair
May Prevent:
Respiratory Syncytial Virus Infections
More Information:
Definitions related to palivizumab:
-
A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.NCI ThesaurusU.S. National Cancer Institute, 2021
-
A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients.NLM Medical Subject HeadingsU.S. National Library of Medicine, 2021
Return to OpenMD Medical Dictionary
> P
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.